Novan to Report Second Quarter 2022 Financial Results on August 11, 2022

Rhea-AI Summary

Novan, Inc. (Nasdaq: NOVN) will report its Q2 2022 financial results on August 11, 2022, at 8:30 a.m. ET. CEO Paula Brown Stafford will lead a conference call and live audio webcast to discuss the operational and financial outcomes. The call will be accessible via phone or through the company's website. Novan focuses on developing innovative dermatological therapies, including SB206, a treatment for viral skin infections, and has recently acquired EPI Health to enhance its commercial capabilities.

Positive

• Acquisition of EPI Health strengthens commercial infrastructure and market presence.
• Pipeline includes SB206 for treating viral skin infections, addressing unmet medical needs.

Negative

• None.

DURHAM, N.C., Aug. 04, 2022 (GLOBE NEWSWIRE) -- Novan, Inc. (“the Company” or “Novan”) (Nasdaq: NOVN), today announced that it will report its second quarter 2022 financial results on Thursday, August 11^th. Novan management will host a conference call and live audio webcast to discuss the operational and financial results at 8:30 a.m. ET that same day.

The call will be led by Paula Brown Stafford, President and Chief Executive Officer of Novan, who will be joined by additional members of the Novan management team. Interested participants and investors may access the conference call by dialing (833) 630-1956 (domestic) or (412) 317-1837 (international) and referencing the Novan, Inc. Conference Call. The live webcast will be accessible on the Events page of the Investors section of the Novan website, novan.com, and will be archived for 90 days.

About Novan

Novan, Inc. is a medical dermatology company primarily focused on researching, developing, and commercializing innovative therapeutic products for skin diseases. Our goal is to deliver safe and efficacious therapies to patients, including developing product candidates where there are unmet medical needs. We are developing SB206 (berdazimer gel, 10.3%) as a topical prescription gel for the treatment of viral skin infections, with current emphasis on molluscum contagiosum.

Novan recently completed the acquisition of EPI Health. EPI Health equips the company with a robust commercial infrastructure across sales, marketing, and communications, as well as fully dedicated market access and pharmacy relation teams. Following the acquisition, the company employs approximately 100 staff, including sales personnel currently covering 42 territories, and promotes products for plaque psoriasis, rosacea, acne and dermatoses. Novan also has a pipeline of potential product candidates using our proprietary nitric oxide-based technology platform, NITRICIL^™, to generate new treatments for multiple indications.

INVESTOR AND MEDIA CONTACT:

Jenene Thomas
JTC Team, LLC
833-475-8247
NOVN@jtcir.com       

FAQ

When will Novan report its second-quarter 2022 financial results?

Novan will report its second-quarter 2022 financial results on August 11, 2022.

What is the purpose of Novan's conference call on August 11, 2022?

The conference call will discuss Novan's operational and financial results for the second quarter of 2022.

Who will lead the Novan conference call on August 11, 2022?

The conference call will be led by Paula Brown Stafford, President and CEO of Novan.

What is SB206 developed by Novan?

SB206 is a topical prescription gel aimed at treating viral skin infections, specifically molluscum contagiosum.